Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Dupilumab for atopic dermatitis

In The Lancet, the LIBERTY AD CHRONOS study by Andrew Blauvelt and colleagues1 of long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids portends a coming revolution in the treatment of atopic dermatitis. Dupilumab seems to be for atopic dermatitis what etanercept was to psoriasis, an effective, safe treatment that might represent a quantum leap forward in our ability to help to improve the lives of patients.1 For individuals with moderate-to-severe atopic dermatitis, quality of life is greatly affected and can be worse than in patients with psoriasis.